Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2013
At a glance
- Drugs Dasatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 09 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.